Monitor FDA interactions closely as resolution of the partial clinical hold is critical for U.S. trial progression, while international trial sites continue enrollment. The upcoming 5 mg/kg data readout in Q1 2026 will be a key catalyst.
Price Chart
Executive Summary
PepGen reported financial results for 2025 and provided updates on its PGN-EDODM1 clinical program for myotonic dystrophy type 1. The company announced a partial clinical hold by the FDA on its FREEDOM2 trial due to preclinical pharmacology and toxicology concerns, while also highlighting positive Phase 1 data and ongoing enrollment in international sites. Financially, the company reduced its net loss year-over-year and maintains a strong cash position into 2027.
Key Financial Metrics
Key Facts
- FDA placed a partial clinical hold on the FREEDOM2 Phase 2 trial due to preclinical pharmacology and toxicology data concerns
- Positive Phase 1 FREEDOM trial data showed dose-dependent splicing correction up to 53.7% at 15 mg/kg with generally well-tolerated safety profile
- Company expects data readouts from the 5 mg/kg cohort in Q1 2026 and 10 mg/kg cohort in 2H 2026
- Cash position of $148.5 million as of December 31, 2025, sufficient to fund operations into the second half of 2027
- Net loss decreased to $89.7 million in 2025 from $90.0 million in 2024
Financial Impact
Reduced net loss from $90.0M to $89.7M year-over-year with cash runway extending into 2027
Risk Factors
- FDA partial clinical hold could delay or prevent U.S. clinical development if not resolved
- Safety signals at higher doses (albuminuria) could impact development path
- Dependence on successful clinical trial outcomes for future value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-091503 |
| Document: pepg-20260304.htm | 0001193125-26-091503 |
| Document: pepg-ex99_2.htm | 0001193125-26-091503 |
| Document: 0001193125-26-091503-index-headers.html | 0001193125-26-091503 |
| Document: 0001193125-26-091503-index.html | 0001193125-26-091503 |
| Document: 0001193125-26-091503.txt | 0001193125-26-091503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.41 $3.18 | ▲ +31.95% | ▲ +31.35% | $2.27 (−6.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.27 (+50.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.27 (+50.00%) |
May 22, 2026 19w ago | EFFECT | $1.51 $1.90 | ▼ −25.83% | ▼ −27.24% | $2.27 (−50.00%) |
May 19, 2026 19w ago | S-3 | $1.38 $1.70 | ▼ −23.19% | ▼ −22.20% | $2.27 (−64.13%) |
May 12, 2026 20w ago | 8-K | $1.78 $1.51 | ▼ −15.17% | ▼ −14.56% | $2.27 (+27.25%) |
Mar 4, 2026 30w ago | 8-K | $5.51 $1.73 | ▼ −68.57% | ▼ −64.79% | $2.27 (−58.86%) |
Mar 4, 2026 30w ago | Insider Cluster | $6.76 $1.74 | ▼ −74.26% | ▼ −69.84% | $2.27 (−66.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access